This trial is evaluating whether Hydroxyurea will improve 1 primary outcome and 2 secondary outcomes in patients with Stroke. Measurement will happen over the course of 6 months.
This trial requires 40 total participants across 2 different treatment groups
This trial involves 2 different treatments. Hydroxyurea is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 2 and have already been tested with other people.
"Significant anemia and SCD are not uncommon in African American and White females in a developing region. In our population, they have similar prevalence and outcome. This suggests that there is unlikely a statistically significant difference between AA and WF with SCD." - Anonymous Online Contributor
"The causes of anemia are complex and need to be viewed in the context of the patient's medical history and physical examination data. In Africa, where most of the world's sickle cell-disease victims are found, the most common cause of anemia is malaria. In this region of the world, malaria is also the leading cause of anemia-associated mortality. In many instances, malaria was also a major reason for moving to urban areas. Many factors interact to cause changes in hemoglobin concentration. In industrialized nations, such as the United States, malaria and sickling defects are rare causes of acute or nonacute anemia." - Anonymous Online Contributor
"Signs and symptoms of anemia in children are not unique to sickle cell disease. Children who are sickle cell disease do not usually present with symptoms of anemia, so it is important for GPs to be alert to the existence of anemia but to seek further investigation if it is identified." - Anonymous Online Contributor
"It has not been definitively proved that anemia and sickle cell trait can be cured. This has not only significant economic and social consequences for a population with a high morbidity of anemia and sickle cell, but also for family members living with sickle-cell-thalassemia." - Anonymous Online Contributor
"Sickle cell anemia arises from heterozygosity of HbS with the normal HbA. It is characterized by shortened life of red blood cells. In the absence of other hemoglobinopathies, it is invariably associated with sickle-cell disease." - Anonymous Online Contributor
"In the United States, anemia is relatively common. In 2012, about 6 million people are believed to have [sickle cell anemia](https://www.withpower.com/clinical-trials/sickle-cell-anemia). In 2012, approximately 16,700 people died of sickle cell disease." - Anonymous Online Contributor
"There are many common treatments for anemia, particularly those with sickle cell disease. Patients with these diseases may benefit from additional treatment based on clinical, diagnostic, and hemoglobin profile evaluation." - Anonymous Online Contributor
"HU has been found to be particularly effective in lowering hemoglobin, particularly in patients with hereditary hemoglobinopathies, such as sickle cell anemia (SCA). We present an analysis of the effect of HU on adult SCA patients and summarize the clinical relevance of these findings through an analysis of the relationship between Hb levels, the number of HbF molecules, and clinical outcomes." - Anonymous Online Contributor
"Increasing Hb levels with hydroxyurea was associated with improved quality of life and life satisfaction but not increased exercise capacity or Hb levels. There was no increased risk of adverse effects with hydroxyurea and no dose response. Prospective trials to study the long-term impact and safety of hydroxyurea and examine the optimal target Hb on QoL for these patients are required." - Anonymous Online Contributor
"Although there is an understanding of the disease pathogenesis, an understanding of the disease process, and guidelines for patient management, more information is needed about how the disease process presents, progresses, and how it differs depending on age. Future prospective studies on the disease process and for patients and their families are warranted, in order to help clinicians provide early diagnosis to avoid complications and to prevent disease progression." - Anonymous Online Contributor
"Hydroxyurea side effects can be as common and as unpleasant as the chronic illness. The side effects of hydroxyurea can be attributed to its ability to block the production of the enzyme ribonuclease (RNase). This inability, in turn, results in a deficiency in a molecule of the enzyme that is essential to the process of RNA and DNA synthesis. In addition, hydroxyurea interferes with heme synthesis. Heme functions depend on the process of metabolism which requires oxygen, and hydroxyurea affects its production. Moreover, hydroxyurea can interfere with the transport of a variety of chemicals, including the antihistamine diphenhydramine, which helps control allergic reactions." - Anonymous Online Contributor
"Anemia and sickle cell (SCD, HbC, or HbS) should be considered for clinical trials. summary: Recent findings assessed the efficacy and safety of different treatment regimens for patients with SCD-related anemia (high red cell distribution width (RDW), normal hematocrit (Hct), or normal Hb)." - Anonymous Online Contributor